Latest Insider Transactions at Ironwood Pharmaceuticals Inc (IRWD)
This section provides a real-time view of insider transactions for Ironwood Pharmaceuticals Inc (IRWD). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of IRONWOOD PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of IRONWOOD PHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 21
2022
|
Andrew Davis SVP, Chief Business Officer |
SELL
Open market or private sale
|
Direct |
3,335
-2.12%
|
$36,685
$11.56 P/Share
|
|
Nov 21
2022
|
Ronald Silver Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
682
-0.65%
|
$7,502
$11.56 P/Share
|
|
Nov 21
2022
|
Sravan Kumar Emany SVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,578
-7.74%
|
$72,358
$11.56 P/Share
|
|
Oct 03
2022
|
Thomas A Mccourt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
18,899
-2.58%
|
$188,990
$10.41 P/Share
|
|
Sep 15
2022
|
Alexander J Denner |
BUY
Grant, award, or other acquisition
|
Direct |
1,374
+1.49%
|
-
|
|
Sep 01
2022
|
Thomas A Mccourt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
26,446
-3.49%
|
$264,460
$10.65 P/Share
|
|
Aug 15
2022
|
Ronald Silver Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,014
-1.88%
|
$22,154
$11.77 P/Share
|
|
Aug 15
2022
|
Jason Rickard SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
994
-0.26%
|
$10,934
$11.77 P/Share
|
|
Aug 15
2022
|
Minardo John Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
7,330
-4.96%
|
$80,630
$11.77 P/Share
|
|
Aug 11
2022
|
Mark G Currie |
SELL
Open market or private sale
|
Direct |
70,000
-11.83%
|
$770,000
$11.78 P/Share
|
|
Aug 09
2022
|
Jason Rickard SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
18,041
-4.57%
|
$198,451
$11.75 P/Share
|
|
Aug 09
2022
|
Jason Rickard SVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,041
+4.37%
|
$198,451
$11.65 P/Share
|
|
Aug 08
2022
|
Jason Rickard SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
29,436
-3.64%
|
$323,796
$11.6 P/Share
|
|
Aug 01
2022
|
Thomas A Mccourt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
23,229
-2.97%
|
$255,519
$11.35 P/Share
|
|
Jun 30
2022
|
Thomas A Mccourt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
19,959
-2.5%
|
$219,549
$11.58 P/Share
|
|
Jun 15
2022
|
Alexander J Denner |
BUY
Grant, award, or other acquisition
|
Direct |
1,222
+1.35%
|
-
|
|
Jun 14
2022
|
Marla L Kessler |
SELL
Open market or private sale
|
Direct |
7,610
-8.29%
|
$83,710
$11.65 P/Share
|
|
Jun 07
2022
|
Mark G Currie |
SELL
Open market or private sale
|
Direct |
190,383
-24.34%
|
$2,284,596
$12.01 P/Share
|
|
Jun 07
2022
|
Mark G Currie |
BUY
Exercise of conversion of derivative security
|
Direct |
190,383
+19.58%
|
$2,094,213
$11.65 P/Share
|
|
Jun 01
2022
|
Andrew Dreyfus |
BUY
Grant, award, or other acquisition
|
Direct |
21,571
+12.45%
|
-
|
|
Jun 01
2022
|
Marla L Kessler |
BUY
Grant, award, or other acquisition
|
Direct |
21,571
+19.03%
|
-
|
|
Jun 01
2022
|
Catherine Moukheibir |
BUY
Grant, award, or other acquisition
|
Direct |
21,571
+17.84%
|
-
|
|
Jun 01
2022
|
Jon R Duane |
BUY
Grant, award, or other acquisition
|
Direct |
21,571
+19.03%
|
-
|
|
Jun 01
2022
|
Julie Mc Hugh |
BUY
Grant, award, or other acquisition
|
Direct |
21,571
+13.36%
|
-
|
|
Jun 01
2022
|
Jay Shepard |
BUY
Grant, award, or other acquisition
|
Direct |
21,571
+21.26%
|
-
|
|
Jun 01
2022
|
Mark G Currie |
BUY
Grant, award, or other acquisition
|
Direct |
21,571
+3.52%
|
-
|
|
Jun 01
2022
|
Alexander J Denner |
BUY
Grant, award, or other acquisition
|
Direct |
21,571
+19.66%
|
-
|
|
May 23
2022
|
Jason Rickard SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
13,537
-1.62%
|
$148,907
$11.5 P/Share
|
|
May 23
2022
|
Michael Shetzline CMO,SVP,Head-Res&Drug |
SELL
Open market or private sale
|
Direct |
10,583
-1.93%
|
$116,413
$11.5 P/Share
|
|
May 23
2022
|
Ronald Silver Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
120
-0.11%
|
$1,320
$11.5 P/Share
|
|
May 23
2022
|
Thomas A Mccourt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
36,308
-1.47%
|
$399,388
$11.5 P/Share
|
|
Mar 24
2022
|
Ronald Silver Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
3,031
-2.8%
|
$36,372
$12.75 P/Share
|
|
Mar 15
2022
|
Catherine Moukheibir |
BUY
Grant, award, or other acquisition
|
Direct |
1,466
+1.85%
|
-
|
|
Mar 15
2022
|
Alexander J Denner |
BUY
Grant, award, or other acquisition
|
Direct |
1,152
+1.7%
|
-
|
|
Mar 14
2022
|
Julie Mc Hugh |
SELL
Open market or private sale
|
Direct |
20,000
-14.45%
|
$220,000
$11.67 P/Share
|
|
Mar 08
2022
|
Thomas A Mccourt Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
248,869
+22.96%
|
-
|
|
Mar 02
2022
|
Minardo John Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
67,873
+31.48%
|
-
|
|
Mar 02
2022
|
Michael Shetzline CMO,SVP,Head-Res&Drug |
BUY
Grant, award, or other acquisition
|
Direct |
81,448
+22.73%
|
-
|
|
Mar 02
2022
|
Ronald Silver Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
47,013
+19.78%
|
-
|
|
Mar 02
2022
|
Jason Rickard SVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,498
+17.81%
|
-
|
|
Feb 28
2022
|
Jason Rickard SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
28,962
-1.68%
|
$289,620
$10.77 P/Share
|
|
Feb 28
2022
|
Michael Shetzline CMO,SVP,Head-Res&Drug |
SELL
Open market or private sale
|
Direct |
17,607
-1.71%
|
$176,070
$10.77 P/Share
|
|
Feb 28
2022
|
Thomas A Mccourt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
48,424
-1.96%
|
$484,240
$10.77 P/Share
|
|
Feb 28
2022
|
Ronald Silver Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,238
-1.19%
|
$22,380
$10.77 P/Share
|
|
Jan 19
2022
|
Thomas A Mccourt Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,290
+8.67%
|
-
|
|
Jan 19
2022
|
Jason Rickard SVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,174
+9.22%
|
-
|
|
Jan 19
2022
|
Michael Shetzline CMO,SVP,Head-Res&Drug |
BUY
Grant, award, or other acquisition
|
Direct |
29,326
+12.1%
|
-
|
|
Dec 22
2021
|
Thomas A Mccourt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
46,327
-7.46%
|
$509,597
$11.41 P/Share
|
|
Dec 16
2021
|
Jason Rickard SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
27,000
-7.78%
|
$297,000
$11.28 P/Share
|
|
Dec 15
2021
|
Catherine Moukheibir |
BUY
Grant, award, or other acquisition
|
Direct |
1,541
+1.98%
|
-
|